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Osteosarcoma is the most common primary bone cancer of children and is established during stages of rapid bone growth. The
disease is a consequence of immature osteoblast diﬀerentiation, which gives way to a rapidly synthesized incompletely mineralized
and disorganized bone matrix. The mechanism of osteosarcoma tumorogenesis is poorly understood, and few proteomic studies
have been used to interrogate the disease thus far. Accordingly, these studies have identiﬁed proteins that have been known to
be associated with other malignancies, rather than being osteosarcoma speciﬁc. In this paper, we focus on the growing list of
available state-of-the-art proteomic technologies and their speciﬁc application to the discovery of novel osteosarcoma diagnostic
and therapeutic targets. The current signaling markers/pathways associated with primary and metastatic osteosarcoma that have
been identiﬁed by early-stage proteomic technologies thus far are also described.
1.Introduction
Osteosarcoma (OS) accounts for approximately 3% of all
childhood cancers [1]. The majority of osteosarcoma cases
arise in children and young adults between 10 and 30
years of age during the years of bone development [1].
Currently, patients diagnosed with localized OS have a 5-
year survival rate between 60 and 80%; however, in those
patients with metastases present at the time of diagnosis
the 5-year survival rate falls dramatically to between 15
and 30% [1]. The current treatment options for patients
withprimaryOSincludechemotherapyandsurgicalremoval
[1]. Osteosarcoma preferentially metastasizes to the lungs
resultinginrespiratoryfailureandpatientdeathiftreatments
are ineﬀective [2, 3].
Osteosarcoma aﬀects the skeleton of patients primarily
in regions of rapid bone growth such as the distal femur,
proximal tibia and proximal humerus [3]. Figure 1(a) shows
a patient MRI with obvious and extensive osteoblastic
changes in the metaphysis of the distal femur with elevation
of the periosteum and diﬀuse intramedullary involvement.
An MRI of the same femur in axial view reveals the extent
of the elevation of the periosteum due to malignant cells
(Figure 1(b)). Several studies have identiﬁed genetic and
epigenetic changes that prevent normal osteoblastic diﬀeren-
tiation from mesenchymal progenitor cells [4–7]a sam a j o r
factor leading to the development of OS [3]. The disease is
characterized by rapidly synthesized osteoid that is produced
by immature osteoblastic cells [8]. These malignant cells and
the immature lace-like osteoid are shown in the histological
appearance of OS (Figures 1(c) and 1(d)). The mechanism
responsible for OS tumorogenesis is poorly understood with
inactivation of tumor suppressor genes and the deregulation
of major bone regulatory signaling pathways, such as Wnt,
bonemorphogeneticprotein(BMP),ﬁbroblastgrowthfactor
(FGF), and hedgehog signaling all implicated [3].
Themajo rityo fOStumo r sar ehet e r oge neous,c haract e r -
ized by the various stages of mesenchymal diﬀerentiation,
each of which demonstrates diﬀerent levels of gene and pro-
tein expression, adding to the complexity of the disease.
Despite the heterogeneity within individual tumors and in-
dividual patients, mutations in p53 and RB have consistently2 Sarcoma
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Figure 1: MRI and histological appearance of osteosarcoma. (a) Coronal view MRI reveals diﬀuse involvement of the distal femur with
elevation of the periosteum (small arrow) and diﬀuse intramedullary involvement (large arrow). (b) Axial view of an MRI reveals elevation
oftheperiosteumduetomalignantcells.(c)Theclassichistologicalappearanceofosteosarcoma.Lace-likepatternosteoidproduction(small
arrow) and malignant cells (large arrow). (d) Higher magniﬁcation of (c) to better appreciate the malignant cells.
beenidentiﬁed[3,9–12].Theseproteinsaremajorregulators
of the cell cycle, and caution should be used when consider-
ing these proteins as therapeutic targets as they may result
in many adverse side eﬀects. The terminal diﬀerentiation of
osteoblasts is controlled by a cascade of regulatory signals
such as BMP, Sonic and Indian hedgehog, and core-binding
factor α-1 (Cbfa1) (also called runt-related gene 2 (Runx2))
[13–15], and therefore, it is unlikely a single treatment tar-
geting a single pathway will be eﬀective [3]. A combination
of drugs that target multiple osteoblastic pathways will likely
be needed to overcome the drug resistance common in OS
[3, 16].
In this paper, we focus on the growing list of available
state-of-the-art proteomic techniques and their application
to the discovery of OS targets and signaling pathways associ-
ated with primary and metastatic OS. These new approaches
provide the rationale to shift the focus of OS research
away from the single-marker/single-pathway paradigm, to a
systems biology approach enabling the analysis of multiple
signaling pathways that are involved in primary OS and
subsequent metastatic disease [17].
2. “Shotgun” Proteomics
Genomic studies provide valuable insight into the regulation
of genes involved in the pathogenesis of disease but are
limited in their ability to identify multiple protein products
derived from individual genes, and it is well established that
mRNA levels do not necessarily correlate to the protein level,
which is the functional output. Proteomics is a technology
forstudyingproteinexpression,protein-proteininteractions,
and posttranslational modiﬁcations from complex mixturesSarcoma 3
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Figure 2: LC MS/MS workﬂow. Proteins can be separated by 2D or SDS-PAGE prior to mass spectrometry. Proteins are digested into
peptides, separated by LC, and identiﬁed by mass spectrometry. The mass spectra are searched in a protein database to identify proteins.
The proteins are quantiﬁed using spectral counting (k is a given protein, SpC is the spectral count, L is the length of the protein, and N is all
proteins identiﬁed in the gel lane) or peak areas in label-free proteomics.
of ﬂuids or tissues that reﬂect the mechanism of disease [17].
Proteomic technologies continue to advance by increasing
the scale of protein identiﬁcation and protein quantiﬁcation
using both label-free and stable isotope labeling techniques
[18–24].
Most proteomic techniques involve a protein separation
step followed by identiﬁcation of proteins. The traditional
protein separation technique used to study OS includes
two-dimensional gel electrophoresis (2DE) followed by
matrix-assisted laser desorption/ionization (MALDI) mass
spectrometry for protein identiﬁcation [8, 25–29]. In 2DE,
proteins are separated by both isoelectric point (pI) and by
molecular weight (MW). The proteins are then extracted
from the gel and digested, and each spot is identiﬁed by mass
spectrometry. This is a tedious process due to the fact each
protein must be spotted individually for MALDI analysis,
and therefore, only small numbers of proteins have been
identiﬁed as diﬀerentiating in OS. Another disadvantage
of this technique is that portions of the proteome such
as low-abundant proteins, membrane-associated or bound
proteins,andproteinswithextremesinpIandMWarerarely
identiﬁed.
More recently, proteomic technologies have greatly
improved both protein separation and protein identiﬁcation
and can be readily applied to oﬀer deeper insight into OS
pathogenesis (Figure 2). One technique is multidimensional
protein identiﬁcation technology (MudPIT), which is a non
gel-based approach that uses 2D liquid chromatography
(LC) for protein separation prior to identiﬁcation by mass
spectrometry [30–32]. MudPIT works by ﬁrst digesting
proteins into peptides, resolving peptides by 2D-LC, and
ﬁnally detecting the peptides by MS/MS [31]. The peptides
areseparatedonapulledmicrocapillarycolumnpackedwith
two independent chromatography phases, which allows for
separation by charge and hydrophobicity to resolve complex
peptide mixtures [33]. The peptides are eluted directly into
the mass spectrometer for peptide identiﬁcation, and the
proteins are identiﬁed by database searching [31, 34]. The
coupling of 2D-LC to tandem mass spectrometry (MS/MS)
wasappliedbyLinketal.[33]forproteome-widestudiesand
isabletoidentifyproteinsfromallsubcellularportionsofthe
cell [31].
The development of MudPIT gave rise to other shotgun
proteomic technologies, which refers to the direct analysis of
complex protein mixtures to rapidly generate a global proﬁle
of the protein complement within a sample mixture [35].
Another shotgun approach is a technique called nanocap-
illary liquid chromatography coupled with tandem mass
spectrometry (nanoLC-MS-MS) [36]. Using this method,
proteins are resolved by standard one-dimensional SDS-
PAGE, and the entire gel lane is excised for trypsin digestion
and analyzed by nanoLC-MS-MS. MudPIT and nanoLC-
MS-MS have similar protein identiﬁcation outputs; there-
fore, both platforms will be useful for OS analysis [36, 37].
3. Bioinformatic Analyses
Diﬀerentiating proteins between normal bone, OS primary
tumors, and metastatic tumors can be accomplished using
spectral counting, that is, the number of tandem mass
spectra assigned to a given protein [37]. This is a label-free
method for protein semiquantitation [38]. Each sample is
subjected to individual LC-MS/MS, and the spectral counts
of identiﬁed proteins are used for direct comparison of sam-
ples. Quantitation of proteins is achieved by comparing the
number of MS/MS spectra for the same protein between two
or more MS/MS analyses. However, it is not always appro-
priate to use raw spectral counts due to the lack of biological4 Sarcoma
replicates and inability to carry out standard statistical anal-
yses in proteomic studies [39]. Therefore, the data must ﬁrst
be normalized before standard statistical analyses can be per-
formed. Zybailov et al. developed a mathematical normal-
ization technique named the normalized spectral abundance
factor (NSAF), which after the natural log of the NSAF value
is calculated, transforms the data into a Gaussian/normal
distribution allowing for statistical testing using the t-test
and other more robust parametric methods [39]. We have
recently applied label-free shotgun proteomics to study mel-
anoma [37]. Proteins were extracted from formalin-ﬁxed
paraﬃn-embedded (FFPE) tissue from melanocytic nevus
a n dm e t a s t a t i cm e l a n o m a .T h es p e c t r a lc o u n t sw e r ei d e n t i -
ﬁed using mass spectrometry, and the data was normalized
by NSAF. A total of 390 proteins were found to be diﬀer-
entially regulated between nevus and metastatic melanoma
[37]. Another method for protein quantitation involves the
alignment of LC MS/MS runs and integrating the peak area
for the peptides [40–42].
An alternative to label-free shotgun proteomics for pro-
teinquantitationincludesstableisotopelabelingapproaches.
These include isotope-coded aﬃnity tag (ICAT) [43–45],
stable isotope labeling by amino acids in cell culture (SILAC)
[43, 46–50], and isobaric tags for relative and absolute
quantiﬁcation (iTRAQ) [51].
4. The CurrentStateof Osteosarcoma
Proteomics
The proteomic technologies discussed above have been dras-
ticallyunderappreciatedinosteosarcomaresearchwithfewer
than 70 analyses published in the last decade (Figure 3),
many of which rely on early stage technologies such as
2DE and MALDI MS. Here we brieﬂy review the proteomic
studiesthathavebeenperformedsince2000,highlightingthe
current prognostic, diagnostic, and predictive biomarkers
identiﬁed from multiple studies thus far (Table 1;[ 8, 25–28,
52–60]).Acompilationofalldiﬀerentiallyexpressedproteins
identiﬁed in these studies can be found in Supplementary
Table 1 available online at doi:10.1155/2012/169416. This
information has provided useful insight into OS tumoroge-
nesis; however, multiple proteins across multiple signaling
pathways that characterize OS are likely to enrich our under-
standing of the hallmarks of cancer [61, 62] that are unique
to OS.
The majority of studies have used diﬀerential protein
expression to identify new protein markers that can be
translated into new diagnostic and therapeutic targets, but
they fail to characterize their global contribution to disease
pathogenesis and instead focus on single marker/single-
pathway identiﬁcations leaving out the complexity of mul-
tiple pathway interactions. Some examples of proteomics
studies which focus mainly on known signaling pathways
instead of taking a more global proteomic approach to
identify the complexity of protein interactions do exist and
are summarized below.
Catesetal.comparedproteinexpressionproﬁlesbetween
two clonally related murine OS cell lines with low (K12) and
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Figure 3: Pubmed Search. The number of research articles
identiﬁed by Pubmed with the search terms “osteosarcoma” and
“proteomics” since 2000. There have been fewer than 70 publica-
tions thus far.
high (K7M2) metastatic potential using two-dimensional
diﬀerence gel electrophoresis (2D-DIGE) and MALDI [26].
2D-DIGE allows direct comparison and relative quantiﬁca-
tion of speciﬁc proteins among diﬀerent samples resolved
together on the same gel using diﬀerent cyanine ﬂuorescent
dyes [63, 64]. They identiﬁed 9 protein peaks by MALDI-MS
with at least a twofold diﬀerence in relative ion intensities
in K7M2 cells compared to K12 cells. 2D-DIGE and tissue
proﬁling identiﬁed 20 proteins, which were uploaded into
Ingenuity Pathway Analysis software identifying 95 addition-
al proteins in promoting metastatic disease. Two cytokines,
macrophage migration inhibitory factor (MIF: NCBI refseq
NM 002415.1) and tumour necrosis factor (TNF: NCBI
refseq NP 000585.2), were chosen for further validation.
TNF and MIF have potential for use as OS biomarkers and
may represent new OS therapeutic targets.
Y. Li et al. compared primary OS to benign bone tumor
samples using 2D gel electrophoresis and the protein spots
identiﬁed with MALDI-TOF MS [28]. They were able
to obtain protein identiﬁcation from 18 out of the 30
diﬀerentiating protein spots from the 2D gel (Table 1). They
identiﬁed cytoskeleton and microtubule-associated proteins,
suggesting they play a role in the tumor cell migration and
metastasis that is characteristic of OS [28].
Zhang et al. took a subcellular comparative approach
[56]. They analyzed proteins in the plasma membrane of
human OS cell line (MG-63) and human osteoblastic cells
(hFOB1.19). Proteins were analyzed through iTRAQ-based
quantitative LC/MS/MS [56]. This is the ﬁrst literature
citation of an LC-MS/MS approach in OS; however, they
identiﬁed only 342 proteins due to their focus on proteins
resident in the plasma membrane. Sixty-eight out of the
342 identiﬁed proteins were diﬀerentially expressed with at
least a 1.5-fold diﬀerence [56]. Cluster of diﬀerentiation
151 (CD151) was chosen for validation using IHC due to
its ability to activate the phosphoinositide 3-kinase (PI3K)
pathway to promote neovascularization [56].Sarcoma 5
Table 1: Commonly identiﬁed proteins from multiple proteomic studies. The ﬁrst column represents the accession number of the protein,
followed by the protein name. The last column contains the author’s last name and year of the publication the protein was found to be
signiﬁcantly diﬀerentiated with the expression level indicated in parentheses.
Accession Protein name References (regulation)
GI: 5453832 150kDa oxygen-regulated protein (precursor) Zhang et al. 2009 [52] (down); Spreaﬁco et al. 2006
[53] (up); Niforou et al. 2008 [25]
P08865 40S ribosomal protein SA Folio et al. 2009 [54] (down); Kang et al. 2006 [55]
(down)
P49189 4-Trimethylaminobutyraldehyde dehydrogenase Guo et al. 2007 [8] (down); Niforou et al. 2008 [25]
P05388 60S acidic ribosomal protein P0 Guo et al. 2007 [8] (up); Kang et al. 2006 [55]( d o w n )
GI: 4916999 78kDa glucose-regulated protein Zhang et al. 2009 [52] (down); Niforou et al. 2008 [25]
P60709 Actin, cytoplasmic 1 Hua et al. 2011 [60] (down); Niforou et al. 2008 [25]
P63261 Actin cytoplasmic 2 Folio et al. 2009 [54] (down); Zhang et al. 2010 [56]
(down); Niforou et al. 2008 [25]
O95433 Activator of 90kDa heat shock protein ATPase
homolog 1 Guo et al. 2007 [8] (up); Niforou et al. 2008 [25]
P30837 Aldehyde dehydrogenase X, mitochondrial (precursor) Kang et al. 2006 [55] (up); Niforou et al. 2008 [25]
GI: 127801853 Alkaline phosphatase, liver/bone/kidney Spreaﬁco et al. 2006 [53] (up); Zhang et al. 2009 [52]
(up)
P06733 Alpha enolase Li et al. 2006 [27] (up); Folio et al. 2009 [54]( d o w n )
P04083 Annexin A1
Cates et al. 2010 [26] (up); Spreaﬁco et al. 2006 [53]
(down); Kang et al. 2006 [55] (up); Niforou et al. 2008
[25]
P07355 Annexin A2 Spreaﬁco et al. 2006 [53] (down); Zhang et al. 2010
[56] (up); Niforou et al. 2008 [25]
P08758 Annexin A5 Liu et al. 2009 [57] (down); Niforou et al. 2008 [25]
O95816 BAG-family molecular chaperone Chang et al. 2008 [58] (down); Niforou et al. 2008 [25]
Q15417 Calponin-3 Guo et al. 2007 [8] (up); Niforou et al. 2008 [25]
P27797 Calreticulin (precursor) Hua et al. 2011 [60] (up); Zhang et al. 2009 [52] (up);
Niforou et al. 2008 [25]
P07339 Cathepsin D precursor Spreaﬁco et al. 2006 [53] (down); Li et al. 2006 [27]
(down)
P12277 Creatine kinase B-type Spreaﬁco et al. 2006 [53] (up); Niforou et al. 2008 [25]
P06730 Eukaryotic translation initiation factor 4E Kang et al. 2006 [55] (down); Niforou et al. 2008 [25]
P15311 Ezrin Li et al. 2010 [28] (up); Folio et al. 2009 [54] (up); Guo
et al. 2007 [8]( d o w n )
P52907 F-actin capping protein subunit alpha-1 Kang et al. 2006 [55] (down); Niforou et al. 2008 [25]
P02792 Ferritin light chain Li et al. 2010 [28] (up); Niforou et al. 2008 [25]
Q02790 FK506-binding protein 4 Guo et al. 2007 [8] (up); Niforou et al. 2008 [25]
P04075 Fructose-bisphosphate aldolase A Kang et al. 2006 [55] (up); Niforou et al. 2008 [25]
P09972 Fructose-bisphosphate aldolase C Chang et al. 2008 [58] (up); Kang et al. 2006 [55] (up);
Niforou et al. 2008 [25]
P09382 Galectin-1 Zhang et al. 2010 [56] (up); Spreaﬁco et al. 2006 [53]
(down); Niforou et al. 2008 [25]
P11142 Heat-shock cognate 71kDa protein Li et al. 2006 [27] (up); Niforou et al. 2008 [25]
Q5IST7 Heat-shock 70 Zhao et al. 2010 [59] (down); Liu et al. 2009 [57] (up)
P11142 Heat-shock cognate 71kDa protein Li et al. 2006 [27] (up); Niforou et al. 2008 [25]
P31943 Heterogeneous nuclear ribonucleoprotein H Kang et al. 2006 [55] (up); Li et al. 2006 [27] (up);
Niforou et al. 2008 [25]
P61 978 Heterogeneous nuclear ribonucleoprotein K Li et al. 2006 [27] (down); Niforou et al. 2008 [25]
P14866 Heterogeneous nuclear ribonucleoprotein L Chang et al. 2008 [58] (up); Kang et al. 2006 [55] (up);
Niforou et al. 2008 [25]
Q15181 Inorganic pyrophosphatase Kang et al. 2006 [55] (down); Niforou et al. 2008 [25]
Q03252 Lamin-B2 Li et al. 2010 [28] (up); Niforou et al. 2008 [25]6 Sarcoma
Table 1: Continued.
Accession Protein name References (regulation)
P07195 L-Lactate dehydrogenase B chain Spreaﬁco et al. 2006 [53] (up); Niforou et al. 2008 [25]
P43243 Matrin-3 Li et al. 2006 [27] (down); Niforou et al. 2008 [25]
P19338 Nucleolin Li et al. 2006 [27] (down); Niforou et al. 2008 [25]
P06748 Nucleophosmin Zhao et al. 2010 [59] (down); Folio et al. 2009 [54]
(down); Niforou et al. 2008 [25]
P35232 Prohibitin
Zhao et al. 2010 [59] (down); Cates et al. 2010 [26]
(up); Kang et al. 2006 [55] (down); Niforou et al. 2008
[25]
P25786 Proteasome subunit alpha type 1 Zhang et al. 2009 [52] (down); Li et al. 2006 [27]
(down); Niforou et al. 2008 [25]
P14618 Pyruvate kinase isozymes M1/M2 Folio et al. 2009 [54] (down); Guo et al. 2007 [8] (up);
Niforou et al. 2008 [25]
Q15459 Splicing factor 3 subunit 1 Chang et al. 2008 [58] (up); Niforou et al. 2008 [25]
P20152 Vimentin
Cates et al. 2010 [57] (up); Li et al. 2010 [28] (up);
Zhang et al. 2010 [56] (up); Zhao et al. 2010 [59]
(down); Zhang et al. 2009 [52] (down); Kang et al. 2006
[55] (down); Li et al. 2006 [27] (up); Zhao et al. 2006
[86] (up); Niforou et al. 2008 [25]
Engin et al. studied the role of Notch signaling in tumors
of mesenchymal origin [65]. Notch has been previously
associated with diﬀerent diseases and cancer [66–69]. A
growing body of evidence supports the idea that Notch
can function either as an oncogene or a tumor suppressor
depending on its expression level [70, 71]. Comparing 7
primary untreated OS samples and 3 posttreatment OS sam-
ples with 3 wild-type osteoblasts by RT-PCR, the expression
of NOTCH1, Notch ligand JAGGED-1, transcription factors
HES-1 and HEY2, direct targets of NOTCH1 signaling,
was signiﬁcantly upregulated in both untreated OS and
posttreatment OS compared with wild-type osteoblasts [65].
They also found the osteoblastic-speciﬁc transcription factor
osterix was upregulated. These data support the notion that
gain of Notch function in committed osteoblasts leads to
proliferation of an immature osteoblastic population and
arrest of osteoblast maturation leading to the development
of OS. Notch can also directly inhibit the master osteoblastic
transcription factor Runx2. Osteoblast function is regulated,
in part, by two speciﬁc transcription factors, Runx-2 and
osterix [16]. They show Notch signaling occurs downstream
of p53 loss of function. In sum, there data suggest that loss
of p53 in a committed osteoprogenitor population leads
to gain of function of Notch signaling with consequences
on cyclins and osterix up-regulation and Runx2 inhibition,
perhaps accounting for proliferative and metastatic potential
of osteosarcomas [65].
Li et al. used a proteomic analysis approach to under-
stand the role of E2F1 in p53-negative tumor cells [27].
E2F1 is a transcription factor that plays an important role in
cell-cycle progression and apoptosis. The overexpression of
E2F1 leads to tumor growth suppression, which makes it an
interesting therapeutic target; however, because it is a master
regulator, the precise mechanisms by which it works need to
be identiﬁed to avoid major side eﬀects. Li and colleagues
studied the eﬀects of E2F1 activity in inducible p53-
deﬁcient Saos-2ERE2F1 OS cells using 2DE and MALDI-
MS. They identiﬁed 33 proteins with 13 proteins coming
from genes annotated as cancer related. E2F1 sensitizes
cells for apoptosis by inhibition of antiapoptotic survival
signals from nuclear factor kappa-B (NF-kappa B) [27]. NF-
kappa B mediates inﬂammatory and antiapoptotic pathways
and has been causally linked to OS lung metastasis [16].
DownstreamtargetsofE2F1includeepidermalgrowthfactor
(EGF), tumor necrosis factor (TNF), interferon gamma
(IFN-gamma), Ca(2+)-induced protein kinase C (PKC),
proteinkinaseA(PKA),themitogen-activatedproteinkinase
(MAPK) pathway, and the nonreceptor tyrosine kinase SRC
[27].
The c-Jun N-terminal kinase (JNK) signal transduction
pathway that is known to play a role in the proliferation,
diﬀerentiation, and apoptosis of osteoblasts in normal bone
has also been studied [72]. These investigators examined
JNK expression by immunohistochemistry (IHC) of OS
specimens in paraﬃn-embedded sections from 56 patients
with high-grade tumor and 15 patients with low-grade
tumor [72]. They assessed the protein levels of two major
JNK isoforms (JNK1 and JNK2), their phosphorylated
(activated) species, p-JNK; their speciﬁc substrate, c-Jun; its
phosphorylated form, pc-Jun; c-Jun heterodimeric partner,
c-Fos. In addition, these studies also examined the alpha
chain of the nascent polypeptide-associated complex (alpha-
NAC),anosteoblastic-speciﬁcAP-1coactivator[72].Positive
staining was observed in OS, with higher protein expression
observed in patients with high-grade tumors compared
with low-grade tumors [72]. The authors conclude that
the proteins identiﬁed as signiﬁcantly diﬀerent between
metastatictumorsandnormalbonemayrepresentacomplex
network of signaling pathways, critical for the development
of OS.Sarcoma 7
Recently, a noninvasive approach for the proteomic
proﬁling of blood from osteosarcoma patients was described
[73]. Using surfaced-enhance laser desorption/ionization-
time of ﬂight (SELDI-TOF) mass spectrometry. They were
abletodistinguishauniqueproteinproﬁlebetweenosteosar-
coma patients and patients with benign bone disease.
In order to improve biomarker discovery, the researchers
developedamethodforthedepletionoftwohighlyabundant
plasma proteins prior to the detection of the low-abundant
proteins [73].
5. Discussion
OS is the primary bone cancer occurring during the second
decade of life and rarely in older adults with Paget’s disease.
These are times in which there is rapid bone development
and turnover. Proteomics has slowly begun to be utilized for
the identiﬁcation of proteins that characterize OS and that
may play a role in OS tumorigenesis (Figure 3). The majority
of the studies thus far have targeted speciﬁc signaling path-
ways of known association with malignancy. For instance,
pathways involved in cell survival and resistance to apoptosis
promote lung metastasis and survival after extravasation to
the lungs, and the proteins found upregulated by proteomic
studies include ezrin, TGF-beta, and apoptotic signaling
intermediates [16]. Ezrin has been found to be upregulated
in osteosarcoma by several research groups [28, 54, 74, 75].
Phosphorylated Ezrin is thought to play a role in early-
stage metastasis by connecting with the target organ site and
therefore is thought to be an ineﬀective treatment strategy
as its function is completed once a metastasis is established
[2]. However, Ren et al. discovered Ezrin phosphorylation
is also present at the leading edge of large metastatic lesions
[75]. Targeting Ezrin could be promising for managing lung
metastases; however, we should shift the focus from target-
ing one protein to identifying the complexity of multiple
protein interactions to improve the eﬃcacy of treatment.
The advancement of proteomics provides the means to
study these complex protein networks and identify the
multiple pathways involved in tumorogenesis, thus shifting
the current research focus of OS away from the single-
marker/single-pathway paradigm to a more systems like
approach.
In addition to proteomics, new technologies are con-
stantly emerging that provide complementary approaches
for the identiﬁcation of disease-speciﬁc biomarkers. Tech-
niques include surface plasmon resonance (SPR) [76–79]
andnanowires/nanotube-basedﬁeldeﬀecttransistors(FETs)
[19, 24, 80, 81]. SPR detects changes in refractive index of
dielectric layer adjacent to the metal ﬁlm due to adsorption
or desorption of molecules on the surface. The optical
surface technique monitors changes in a real-time manner.
SPR has been used for biomarker discovery in colon cancer
[82], ovarian cancer [83], and pancreatic cancer [84].
Nanowires/nanotubes are used to target speciﬁc low-
molecular-weight proteins. The platform consists of an elec-
trochemical immunosensor, which consists of multiwalled
carbonnanotubesforreal-timedetectionofcancerbiomark-
ers in human serum [19]. The technology binds candidate
proteins to the functionalized nanowires/nanotubes, leading
to a detectable alteration in electrical conductance of the
device [19]. Nanowires have been used for biomarker dis-
covery in prostate cancer [24, 81] and myocardial infarction
[85].
Althoughexciting,thesebiomarkerdiscoveryapproaches
are currently in the proof-of-concept stage and have been
used for targeted discovery of low-abundant proteins in
human serum and not for de novo protein identiﬁcation.
Complementing proteomic-based biomarker platforms with
these new approaches may indeed provide the sensitivity and
speciﬁcity needed for a comprehensive analysis of OS. In
sum, we eagerly await the impact of these evolving technolo-
gies on the pathophysiology, diagnosis, and treatment of OS.
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